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Point by point response 
 
Dear Editor, 
 
We would like to thank the reviewers for their very detailed and constructive feedback. 
Please find below our point by point response. 
Please note that the changes/additions in the text are highlighted in yellow. 
 
Response to Reviewer #1: 
 
1) "The tumor is referred to as sebaceous cell carcinoma in this paper. All 7 references in the 
bibliography and most textbooks call this malignancy sebaceous carcinoma”.  
 
Thank you for this point - we agree - and have corrected the terminology throughout the case report to this effect. 
 
2) "As a general rule, when placing an exceptionally rare or unusual diagnosis in the literature, a 
certain level of "proof" is required. In the first case of primary sebaceous carcinoma the 
histopathology shows an undifferentiated tumor and the immunohistochemical stains for 
adipophilin were not adequate to interpret in grey scale.” 
 
Thank you - we agree that the image provided was of low magnification, and therefore difficult to interpret in grey 
scale. We have corrected this by providing a higher magnification image of the Adipophilin stain in the tumour 
cells (as Figure 2D).  
 
We have also provided images of the second case (Figure 4A-D). 
 
Please note that the tumour cells of both cases, showed an immunohistochemical profile consistent with 
sebaceous carcinoma, namely: EMA+, Ber-EP4+, Adipophilin+ and Androgen receptor positive. This was not 
stated in the original text, but we provide an image of the AR stain in the second case. 
 
Unfortunately, we can no longer add in micron bars into the original images, as these were taken on an old 
photographic system. 
 
 
 
3) In the Introduction it states "Sebaceous cell carcinoma is an aggressive malignancy with a high 
mortality rate….". Then 2 sentences later it reads: "It may also exhibit local invasive behavior or 
metastasize…". It seems unnecessary to remind the reader the tumor is also locally invasive 
when you just mentioned it could kill him or her. 
 
Thank you for the suggested alterations to the text: we have made these where appropriate. 
 
4) In Case 2 it does not mention the side that the primary eyelid sebaceous occurred on. I assume 
the same side as the lacrimal sac, but I would explicitly state such. 
 
Indeed, this was on the same side (i.e. right side). The text was changed accordingly. 
 
 
 
Response to Reviewer #2: 
 
1) Both cases of SGC were proven by histopathology. The first case had poor vision in the fellow eye for 
which globe salvaging surgery was done. Why did the authors not think of neo-adjuvant chemo therapy 
(NACT) described in orbital sebaceous carcinoma. A series of orbital SGC has been reported by Kaliki S 
et al and found good response to NACT. The down staging of the SGC by NACT may have helped 
globe/vision salvaging surgery in one or both cases. Authors will need to comment why they did not 
consider NACT? 
 
Thank you for highlighting this important aspect of management. We agree that NACT has shown promising 
results in early reports, however the role of chemotherapy has not been well defined in SGC yet. A few case 
reports and series existed at the time of treatment of patient 1 describing use of chemotherapy to shrink tumour 
mass prior to surgical excision (eg Kalili’s group 2015, 10 cases; Murthy 2005- case with regional LN mets). 
However, these described mostly larger tumours in younger patients than ours mostly with lymph node 
involvement (Naik’s cases T3 n=6, N1=6, M1 n=2). The patient was discussed in skin cancer MDT and since 
there was no LN involvement and the tumour was resectable without NACT, the evidence for NACT was not felt 
Response to Reviewers
to be compelling, and after discussion with the patient the option of urgent surgical resection followed by highly 
focal IMRT was chosen. We have now pointed this out in the discussion section. 
 
2) Abstract is not structured. It will help readers if the authors provide a structured abstract highlighting 
the atypical mode of spread in SGC. 
We have modified the abstract to highlight the atypical mode of the spread, however the journal requirements 
indicate an unstructured format for case report abstracts.  
 
3) Case report 2 describing SGC in 85 yr old female fails to mention the duration of follow-up. 
Duration of follow-up is three years for case 2. Also patient 1 follow-up duration was updated in the text (now 2.5 
years post-op). 
 
 
4) Both cases do not mention the TNM staging as per AJCC. 
TNM staging was added to both according to AJCC eight edition for eyelid cancers and the reference section 
was updated accordingly.  
 
 
 
Response to Reviewer #3: 
 
1) For the case no 2, please mention the follow up duration. 
    Duration of follow-up is three years for case 2. This is now mentioned in the text. 
 
 
2) For the case no 1, since the follow up is for 2 years, it would be great to have a post op picture in the 
collage. 
    We have now included a photo (Figure 1E) from most recent follow-up (2.5 years post-op) 
 
3) Please mention a line about the possible plan for lacrimal rehabilitation in the patient no 1. 
    In terms of lacrimal rehabilitation, patient number 1 underwent successful insertion of Lester Jones tube. This     
is now highlighted in the text. 
 
 
We would like to thank the Reviewers again for their suggestions, which has led to an improvement in the 
manuscript. 
 
With kind regards, 
 
 
 
Dr Kaveh Vahdani (on behalf of my co-authors). 
Précis 
We describe two rare cases sebaceous carcinoma in the lacrimal sac presenting as a 
medial canthal mass simulating chronic dacryocystitis. 
 
Precis
Abstract 
Sebaceous carcinoma is an aggressive malignancy with a high mortality rate that 
commonly arises in the periorbital area. Rarely the lacrimal apparatus may be involved 
by either contiguous or non-contiguous spread. The authors describe two unusual 
cases of sebaceous carcinoma in the lacrimal sac presenting as a medial canthal 
mass simulating chronic dacryocystitis. In case 1, the sebaceous carcinoma occurred 
primarily in the lacrimal sac, in the absence of concurrent or previous ocular adnexal 
sebaceous neoplasia. Mapping biopsies found no evidence of intraepithelial disease. 
Case 2 developed a late non-contiguous disease recurrence involving the lacrimal sac 
five years post-primary resection of an ipsilateral eyelid sebaceous carcinoma. These 
cases demonstrate atypical mode of spread of sebaceous carcinoma into lacrimal 
excretory system. It is important to regard the nasolacrimal drainage system as a 
potential reservoir for neoplastic sebaceous cells and minimise the risk of tumour cell 
dissemination during surgical management of eyelid or conjunctival sebaceous cell 
tumours. 
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Abstract 47 
Sebaceous carcinoma is an aggressive malignancy with a high mortality rate that 48 
commonly arises in the periorbital area. Rarely the lacrimal apparatus may be involved 49 
by either contiguous or non-contiguous spread. The authors describe two unusual cases 50 
of sebaceous carcinoma in the lacrimal sac presenting as a medial canthal mass 51 
simulating chronic dacryocystitis. In case 1, the sebaceous carcinoma occurred primarily 52 
in the lacrimal sac, in the absence of concurrent or previous ocular adnexal sebaceous 53 
neoplasia. Mapping biopsies found no evidence of intraepithelial disease. Case 2 54 
developed a late non-contiguous disease recurrence involving the lacrimal sac five years 55 
post-primary resection of an ipsilateral eyelid sebaceous carcinoma. These cases 56 
demonstrate atypical mode of spread of sebaceous carcinoma into lacrimal excretory 57 
system. It is important to regard the nasolacrimal drainage system as a potential reservoir 58 
for neoplastic sebaceous cells and minimise the risk of tumour cell dissemination during 59 
surgical management of eyelid or conjunctival sebaceous cell tumours. 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
MAIN TEXT 70 
Introduction 71 
Sebaceous carcinoma is an aggressive malignancy with a high mortality rate that 72 
commonly arises in the periorbital area, usually in the eyelid. The tumour is well known 73 
for mimicking other periocular lesions, often leading to delayed diagnosis or misdiagnosis.  74 
[1-6] The authors describe two unusual cases of sebaceous carcinoma in the lacrimal 75 
sac, presenting as a medial canthal mass simulating chronic dacryocystitis. Patient 76 
consent has been obtained for publication of the medical photography included in the 77 
article. This report adhered to the ethical principles outlined in the Declaration of Helsinki 78 
as amended in 2013. 79 
 80 
Case 1 81 
A 74-year-old woman was referred with a one-year history of right epiphora followed by 82 
a firm, non-tender swelling at the right medial canthus present for 6 months [Fig 1 A] and 83 
mimicking a chronic dacryocystitis. Imaging of orbits/sinuses with contrast demonstrated 84 
an enhancing mass within the medial aspect of the right orbit centered on the lacrimal 85 
sac, displacing the globe laterally with extension into the nasolacrimal duct, with 86 
obstruction of the frontal sinus drainage and osteomeatal complex. [Fig 1 B-C] 87 
Incisional biopsy of the lacrimal sac mass revealed a poorly differentiated carcinoma 88 
composed of small-to-medium sized cells with oval nuclei, prominent nucleoli and foamy 89 
cytoplasm. On immunohistochemistry, the cells demonstrated positivity for epithelial 90 
membrane antigen (EMA), Ber-EP4, and focally for adipophilin. [Fig 2] On the basis of 91 
the morphological and immunohistochemical findings, the diagnosis of sebaceous 92 
carcinoma was made. [Fig 2] Conjunctival mapping biopsies did not identify pagetoid 93 
intraepithelial disease. Based on American Joint Committee on Cancer (AJCC) eighth 94 
edition8 the staging of the tumour was: T4bN0cM0. Following a multidisciplinary team 95 
discussion, the option of potentially curative exenteration with ethmoidectomy and 96 
maxillectomy was proposed; however, due to poor vision in the contralateral eye (OS = 97 
1/60 caused by previous central retinal vein occlusion), it was decided to perform a globe-98 
sparing surgical de-bulking of the tumour with adjuvant radiotherapy to medial orbit and 99 
maxilla.  100 
Intraoperatively, the globe was found to be separate from the tumour that appeared to 101 
have been resected in toto. Post-operatively, vision and eye motility have been preserved 102 
at 2.5 years follow-up with no evidence of local or distant recurrence. (Fig 1E). She also 103 
underwent successful lacrimal bypass tube surgery (Lester Jones tube) for lacrimal 104 
rehabilitation. 105 
 106 
Case 2 107 
An 85-year-old woman was referred with a right medial canthal mass and epiphora.  She 108 
had previous local resection of a small right upper eyelid sebaceous cell carcinoma five 109 
years prior at a different unit. CT images demonstrated a soft tissue mass within the right 110 
lacrimal sac, which extended into the nasolacrimal duct but without post-septal extension. 111 
MRI scan also illustrated an enhancing soft tissue mass within the right lacrimal sac. The 112 
mass appeared separate from the extraocular muscles and there was no extension into 113 
the orbital fat. [Fig3] MRI neck, chest, abdomen and pelvis did not find evidence of 114 
metastatic disease. 115 
Incisional biopsy of the lacrimal sac lesion diagnosed a sebaceous cell carcinoma, on the 116 
basis of morphological and immunohistochemical (EMA+, Ber-EP4+, Adipophilin+ and 117 
androgen receptor+) findings. [Fig4] Conjunctival mapping biopsies excluded 118 
intraepithelial spread or invasive sebaceous cell carcinoma. (AJCC staging T4bN0cM0) 119 
Subsequently, the patient underwent orbital exenteration with adjuvant radiotherapy. 120 
Post-operatively she developed recurrent wound infections requiring hospitalisation and 121 
intravenous antibiotics. Further CT orbits demonstrated a persistent fistula from the 122 
ethmoid sinus following exenteration, which required surgical repair with a local 123 
advancement flap. Three years postoperatively, there has been no evidence or recurrent 124 
disease. 125 
 126 
DISCUSSION 127 
Sebaceous carcinomas derived from neoplastic cells of sebaceous glands, most 128 
commonly located within the meibomian glands of the tarsus, but also potentially from 129 
Zeis glands, caruncle, pilo-sebaceous units within the eyebrow skin. Eyelid sebaceous 130 
carcinoma may spread locally by invading the adjacent epithelia or the orbital soft tissues, 131 
lacrimal secretory apparatus or cranial cavity in advanced cases. [1] New 132 
immunohistochemical markers on fixed material (e.g. adipophilin) aid the diagnosis of 133 
sebaceous carcinoma [7].  134 
 135 
Involvement of the lacrimal excretory system by contiguous spread is rare. Margo et al. 136 
reported a case of widespread intraepithelial sebaceous carcinoma of the conjunctiva and 137 
skin of the eyelid with contiguous extension into the introitus of the lower canaliculus. [4] 138 
Khan et al. discovered pagetoid canalicular involvement in three cases in which the 139 
canaliculus was excised at the time of the surgery. They also found prelacrimal tumour 140 
spread to the nasolacrimal duct with tumour mass in the inferior turbinate in another case. 141 
[5]. All these cases had documented intraepithelial conjunctival or cutaneous spread, in 142 
contrast to our cases.  143 
 144 
Rath et al. described a case of sebaceous carcinoma of the eyelid metastasizing to the 145 
ipsilateral lacrimal sac five years after complete primary excision. No mapping biopsies 146 
were performed at the time of the primary surgery. Imaging showed a mass in the lacrimal 147 
sac with bony erosion. Histopathology confirmed sebaceous carcinoma of the lacrimal 148 
sac but no infiltration of the nasolacrimal duct or conjunctiva were identified. [6] Literature 149 
review did not detect any previous cases of sebaceous carcinoma primarily arising in the 150 
lacrimal sac.  151 
 152 
The mechanism of tumour spread into the lacrimal outflow system is uncertain. Two 153 
patterns have been postulated. Relatively contiguous tumours are believed to follow a 154 
pagetoid intraepithelial dissemination route. Whereas, widely separated non-contiguous 155 
areas of tumour involvement may suggest free-floating tumour cells are carried in the 156 
tears (so-called oncorrhoea) and seeded in the lacrimal drainage system via the 157 
canalicular aqueous flow. This implantation via tear film may also account for the non-158 
contiguous conjunctival multicentric lesions or skip lesions. A combination of both 159 
mechanisms may also be accountable. [1, 5] 160 
 161 
Both our cases had rather unusual presentations with unclear mechanism of tumour cell 162 
spread. In case 1, the invasive tumour occurred primarily in the lacrimal sac, which is 163 
devoid of sebaceous glands. This patient had no previous history of eyelid or adnexal 164 
malignancy nor any evidence of intraepithelial disease on mapping biopsies. A 165 
hypothetical explanation could be the presence of an ectopic (choristomatous) sebaceous 166 
gland [4] within the lacrimal sac, leading to a subsequent malignant transformation. It has 167 
been suggested that extraorbital sebaceous cell carcinoma involving the parotid gland 168 
may arise from pluripotent or ectopic cells retained during embryological development. 169 
[1]   Another hypothesis is sebaceous gland metaplasia of the lacrimal sac epithelium with 170 
subsequent malignant transformation. However, it is extremely difficult to prove any of 171 
these theories. A further possibility is the presence of a previous small occult tumour 172 
resulting in distal implantation of free-floating cancer cells via the tear film.  173 
 174 
Case 2 developed a late non-contiguous disease recurrence involving the lacrimal sac 175 
five years post-primary resection, similar to one described by Rath et al. [6] Our case 176 
additionally exhibited an extension of tumour into the nasolacrimal duct. Mapping biopsies 177 
did not show any evidence of pagetoid spread. We presume that malignant cells were 178 
transported by tears and implanted in the lacrimal sac, as previously suggested in the 179 
literature. [5, 6] The delayed involvement of the lacrimal sac in this case diminishes the 180 
likelihood of a multicentric synchronous disease. 181 
 182 
Wide local excision with margin control or Mohs micrographic surgery represent the 183 
mainstay of management. [9,10] Chemotherapy and radiotherapy may also be useful in 184 
recurrent or metastatic disease. Although the field is evolving, the role of chemotherapy 185 
has not been well defined in sebaceous carcinoma. Previous reports have described the 186 
utility of neoadjuvant chemotherapy (NACT) by downstaging the sebaceous carcinoma 187 
and aiding globe salvaging surgery, however these mainly included younger patients with 188 
mostly lymph node metastasis. [11,12]. The management of case 1 in our study was 189 
discussed in skin cancer multidisciplinary team and since there was no lymph node 190 
involvement and the tumour was considered resectable without NACT, as well as the 191 
paucity of evidence for NACT, the option of urgent surgical resection followed by highly 192 
focal Intensity-modulated radiation therapy (IMRT) was agreed, following discussion with 193 
the patient. 194 
 195 
Our cases demonstrate the notorious diverse presentation of sebaceous carcinoma, and 196 
the importance of close clinicopathological correlation. The first case presented as a 197 
primary sac tumour in the absence of concurrent or previous ocular adnexal sebaceous 198 
neoplasia. The importance of urgent imaging and biopsy of suspicious medial canthal 199 
masses is paramount. Regular and long-term follow-up is vital as recurrence or metastatic 200 
disease can occur many years after primary surgery. It is also important to regard the 201 
nasolacrimal drainage system as a potential reservoir for neoplastic sebaceous cells and 202 
minimise the risk of tumour cell dissemination during surgical management of eyelid or 203 
conjunctival sebaceous cell tumours. [1] 204 
 205 
 206 
 207 
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LEGENDS 241 
Figure 1. (A) Medial canthal mass masquerading as chronic dacryocystitis. (B) axial and 242 
(C) coronal CT illustrate a right lacrimal mass invading the medial orbit, ethmoidal sinus 243 
and nasolacrimal duct (D) T2-weighted MRI demonstrates a fairly homogeneous mass in 244 
the lacrimal sac. (E) Clinical appearance at 2.5 years follow-up with no evidence of 245 
recurrence. 246 
 247 
Figure 2. A) Histopathological sections revealed a poorly-differentiated carcinoma, 248 
completing filling the lacrimal sac and invading into the adjacent stroma (Haematoxylin 249 
and Eosin (H&E), x 10 objective). B) On higher power, the foamy cytoplasm of the 250 
pleomorphic cells can be seen (H&E stain, x 20 objective). C) Adipophilin stain 251 
demonstrates focal positivity of this marker within the cytoplasm of some of the cells 252 
(DAB, x20 objective) Square box highlights area of higher magnification in image D). D) 253 
Patchy adipophilin positivity in sebaceous carcinoma cells with clear negativity seen in 254 
the adjacent lymphocytic infiltrate (DAB, x40 objective). 255 
 256 
Figure 3. ( A) Axial and(B) Coronal CT show soft tissue in the lacrimal sac extending into 257 
superior part of the nasolacrimal duct, (C) enhancement of the mass in post-gadolinium 258 
T2 weighted MRI. 259 
 260 
Figure 4. (A) Histological section stained with Haematoxylin and Eosin of the incision 261 
biopsy of the lacrimal sac mass demonstrated a moderate to poorly-differentiated invasive 262 
tumour occurring in nests as well as single cells, separated by fibrotic bands, and showing 263 
a brisk mitotic count (H&E, objective 20x).  264 
(B) Strong membranous positivity of the tumour cells for Ber-EP4 (DAB, objective 40x).  265 
(C) Globular positivity of adipophilin in the cytoplasm of the carcinoma cells, which also 266 
extend into the surgical resection margin (DAB, objective 60x). (D) Nuclear positivity of 267 
the tumour cells for androgen receptor in a better differentiated region of the tumour (DAB, 268 
objective 40x). 269 
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